News Search Results
Aug 08, 2024, 06:59 ET Q32 Bio Reports Second Quarter 2024 Financial Results and Provides Corporate Update
Aug. 8, 2024 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing biologic therapeutics to restore immune homeostasis, today reported financial results for the quarter ended
More news about: Q32 Bio
Aug 08, 2024, 06:45 ET Lilly Reports Q2 2024 Financial Results, Raises Full-Year Revenue Guidance by $3 Billion
life-changing discoveries for nearly 150 years, and today our medicines help more than 51 million people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges:
More news about: Eli Lilly and Company
Aug 08, 2024, 06:30 ET Immunic, Inc. Reports Second Quarter 2024 Financial Results and Provides Corporate Update
Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today
More news about: Immunic, Inc.
Aug 07, 2024, 17:00 ET Eupraxia Pharmaceuticals Reports Second Quarter 2024 Financial Results
Aug. 7, 2024 /PRNewswire/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ: EPRX) (TSX: EPRX), a clinical-stage biotechnology company leveraging its proprietary DiffuSphere™ technology to optimize drug delivery for applications with significant unmet need, today announced
More news about: Eupraxia Pharmaceuticals Inc.
Aug 07, 2024, 16:05 ET Relmada Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
Aug. 7, 2024 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, "Relmada", "the Company"), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today provided a corporate update and announced preliminary and unaudited financial
More news about: Relmada Therapeutics, Inc.
Aug 07, 2024, 16:05 ET Spyre Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update
Aug. 7, 2024 /PRNewswire/ -- Spyre Therapeutics, Inc. ("Spyre" or the "Company") (NASDAQ:SYRE), a clinical-stage biotechnology company utilizing best-in-class antibody engineering, rational therapeutic combinations, and precision medicine approaches to target improved efficacy
More news about: Spyre Therapeutics, Inc.
Aug 07, 2024, 16:05 ET Tyra Biosciences Reports Second Quarter 2024 Financial Results and Highlights
Aug. 7, 2024 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology,
More news about: Tyra Biosciences
Aug 07, 2024, 16:05 ET ODDITY TECH REPORTS RECORD SECOND QUARTER RESULTS, RAISES OUTLOOK
business headquarters in New York City, an R&D center in Tel Aviv, Israel, and a biotechnology lab in Boston. Contacts: Press:Michael Braun
More news about: Oddity Tech Ltd.
Aug 07, 2024, 14:00 ET NeuroSense Therapeutics Announces Private Placement with Senior Management Participation at Premium to Market Price
NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, today announced the entry into a definitive agreement with certain investors
More news about: NeuroSense
Aug 07, 2024, 10:36 ET Plonts Plant-Based Cheese Launches with $12M Seed Round in New York City, San Francisco
pilot plant in Oakland, California. Plonts is making a new category of plant-based foods using an ancient biotechnology: fermentation. They use the same process that turns milk into cheese to turn plants into cheese, but they start with soy milk instead of cow's milk.
More news about: Plonts
Aug 07, 2024, 10:01 ET Functional Service Providers (FSP) Market 2024-2031 | Transform Your Business Strategy with InsightAce Analytic Detailed Report
Market Dynamics: Drivers- Rising R&D investments, especially in the biopharmaceutical and biotechnology industries, have created a need for Functional Service Providers (FSPs) in the global market. They provide highly qualified research associates,
More news about: InsightAce Analytic Pvt. Ltd
Aug 07, 2024, 09:20 ET Centrus Board Adds Two Members With Key National Security, Industry, and Nuclear Expertise
the CIA's DS&T, where her responsibilities included systems acquisition and research and development in fields ranging from power sources to biotechnology. Ms. O'Sullivan joined the CIA in 1995 after working for the Office of Naval Intelligence and TRW. Ms. O'Sullivan's appointment, effective
More news about: Centrus Energy Corp.
Aug 07, 2024, 09:00 ET Origin Agritech Appoints Li Yang as Chief Operating Officer and Board Director
the Bio-Safety Certificate from China's Ministry of Agriculture. Over the years, Origin has established a robust biotechnology seed pipeline, including products with glyphosate tolerance and pest resistance (Bt) traits. For further information, please visit the Company's
More news about: Origin Agritech Limited
Aug 07, 2024, 08:39 ET The Silky Smooth Fish Oil Making Omega-3 Supplements Easier to Stomach
Utrecht in the Netherlands. The founder and CEO is a fish oil expert with a master's degree in biotechnology from the renowned Dutch Wageningen University (an elite institution that focuses on health, nutrition, and agricultural studies). As a father of
More news about: Arctic Blue
Aug 07, 2024, 08:32 ET Explaining DHA and EPA Omega-3 Fatty Acids in Fish Oil
Utrecht in the Netherlands. The founder and CEO is a fish oil expert with a master's degree in biotechnology from the renowned Dutch Wageningen University (an elite institution that focuses on health, nutrition, and agricultural studies). As a father of
More news about: Arctic Blue
Aug 07, 2024, 08:00 ET Formosa Pharma and Eyenovia Announce Initiation of Co-Development of Clobetasol Propionate Ophthalmic Suspension, 0.05%, for the treatment of Acute Dry Eye Disease in United States
Optejet® dispenser technology." About Formosa Pharmaceuticals, Inc. Formosa Pharmaceuticals, Inc. (6838.TWO) is a clinical stage biotechnology company with primary focus in the areas of ophthalmology and oncology. The company's proprietary nanoparticle formulation technology (APNT®),
More news about: Formosa Pharmaceuticals Inc.,
Aug 07, 2024, 07:00 ET Ayana Bio Welcomes Biotechnology Veteran Jill Zullo to its Board of Directors
Director Biointermediates at Cargill, to the company's Board of Directors. Dr. Zullo is an experienced commercial leader with deep technical roots in biotechnology who has built new businesses in several markets.
More news about: Ayana Bio
Aug 07, 2024, 07:00 ET WILLOW BIOSCIENCES ANNOUNCES NEW FUNDED BIOPESTICIDES RESEARCH AND DEVELOPMENT PARTNERSHIP AFTER SUCCESSFULLY COMPLETING FEASIBILITY STUDY
Aug. 7, 2024 /PRNewswire/ - Willow Biosciences Inc. ("Willow" or the "Company") (TSX: WLLW) (OTCQB: CANSF), a leading biotechnology company focused on revolutionizing industrial manufacturing of pure, consistent, and sustainable ingredients, announces that it has signed a fully
More news about: Willow Biosciences Inc.
Aug 07, 2024, 07:00 ET Mediar Therapeutics Initiates Second Clinical Program in Portfolio of Novel First-In-Class Antibodies Designed to Halt Fibrosis
Mediar Therapeutics, Inc., a clinical stage biotechnology company advancing a portfolio of first-in-class therapies designed to halt fibrosis progression, today announced the first cohort of participants
More news about: Mediar Therapeutics
Aug 07, 2024, 06:30 ET BIO-TECHNE DECLARES DIVIDEND
acceptance of new products, the funding and focus of the types of research by the Company's customers, the impact of the growing number of producers of biotechnology research products and related price competition, general economic conditions, customer site closures or supply chain issues, the impact of currency
More news about: Bio-Techne Corporation
Aug 07, 2024, 06:30 ET BIO-TECHNE RELEASES FOURTH QUARTER FISCAL 2024 RESULTS
one of the world's leading suppliers of specialized proteins such as cytokines and growth factors, immunoassays, antibodies and reagents, to the biotechnology and academic research communities. Additionally, the segment provides an array of platforms useful in various areas of protein analysis. Protein
More news about: Bio-Techne Corporation
Aug 07, 2024, 06:00 ET Sanyou Pharmaceuticals and JiAnTeBo Biotechnology Forge Strategic Partnership to Jointly Develop New Agonist Antibody Drugs
Sanyou Biopharmaceuticals (Shanghai) Co., Ltd. (hereinafter referred to as "Sanyou Bio") and Guangdong JiAnTeBo Biotechnology Co., Ltd. (hereinafter referred to as "JiAnTeBo") have signed a strategic cooperation agreement. Under the leadership of Professor Yin Zhinan,
More news about: Sanyou Bio
Aug 07, 2024, 05:32 ET Global Biorefinery Market Set to Reach Nearly $1.2 Trillion by 2029: Products and Applications
RENEWABLE ENERGY GROUPENVIVA INC.HONEYWELL UOP (HONEYWELL INTERNATIONAL INC.)NESTENOVOZYMES A/SPLANET BIOTECHNOLOGY INC.POET LLC.PETROBRASSEABOARD ENERGYVANCE GROUP LTD.VALERO ENERGY CORP.WILMAR INTERNATIONAL
More news about: BCC Research LLC
Aug 06, 2024, 16:05 ET Heron Therapeutics Announces Second Quarter 2024 Financial Results and Narrows Financial Guidance
Aug. 6, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced financial results for the three and six months ended June 30, 2024, and highlighted recent
More news about: Heron Therapeutics, Inc.
Aug 06, 2024, 16:01 ET Rigel Reports Second Quarter 2024 Financial Results and Provides Business Update
Calif., Aug. 6, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today reported financial results for the second quarter ended June 30,
More news about: Rigel Pharmaceuticals, Inc.